Endpoints. The primary endpoints are occurrence of all adverse events including but not limited to: · all MIs · cardiovascular hospitalization · serious ventricular arrhythmias sustained · VT (symptomatic or sustained VT [duration longer than 30 seconds or 100 beats, or associated with hemodynamic collapse] · VF · symptomatic bradycardia, pauses of longer than 3.0 seconds, complete atrioventricular block, Mobitz II atrioventricular block · symptomatic heart failure (NYHA criteria + physical examination OR hospitalization due to heart failure) · renal failure · stroke · death Secondary Endpoints include the parameters: · change from baseline in LV dimensions (end-systolic volume index, end-diastolic volume index, left ventricular mass) · change from baseline in regional (infarct related) and global wall motion score · change from baseline in ejection fraction · cardiac rupture · NT-proBNP
Endpoints. Except as otherwise expressly stated to the contrary in the applicable Cloud Offer Definition or any quotation, Distributor is not responsible for the provision of any end points or similar devices necessary to deploy Cloud Services for any Cloud End User, including personal end points, personal computers, mobile devices and telepresence or room systems.
Endpoints. The incidence and course (timing, location of pain and duration) of myalgia after conditioning were the primary endpoints. Secondary endpoint was pain severity according to the WHO pain relief ladder. Other variables noted above were collected to evaluate potential predisposing factors. Statistical analysis Descriptive statistics, such as median and frequency, were used to summarize baseline characteristics and outcomes. Odds ratios (OR) were estimated by means of logistic regression to examine the association between conditioning regimen (TREO-based vs. BU-based) and myalgia and adjusted for possible confounding (hemoglobinopathies versus other indications). In the TREO cohort, univariable and multivariable logistic regression was performed to assess whether baseline- or transplant characteristics (age, underlying disease, conditioning regimen, treosulfan exposure) were prognostic for the development of myalgia. All P-values were 2-tailed and considered significant when P<0.05. Statistical 5 analyses were performed using R version 3.6.1 and RStudio version 1.2.5019.
Endpoints. (i) Avaya shall use its commercially reasonable efforts to cause (x) the Avaya Endpoints existing as of the Effective Date to be, as soon as reasonably practicable following the Effective Date, and (y) future Avaya Endpoints to be, at all times prior to such Avaya Endpoints being Sold, in each case, compatible with ACO and the other RingCentral Services, and (ii) RingCentral shall use its commercially reasonable efforts to cause (x) the RingCentral Services existing as of the Effective Date to be, as soon as reasonably practicable following the Effective Date, and (y) future RingCentral Services to be, at all times prior to the RingCentral Services being Sold, in each case, compatible with the Avaya Endpoints. To the extent an Avaya Endpoint and the RingCentral Services are so compatible, RingCentral shall offer such Avaya Endpoint as part of its and its Subsidiaries’ product catalogs at least as prominently and positively in the ordinary course of business, in all material respects, as any other RingCentral Offering that is designed to provide substantially similar functionality (taken as a whole) and is then‑currently Marketed in such product catalogs in the ordinary course of business. Each Party acknowledges that the other Party’s performance of its obligations under this Section 2.3(e) depends on such Party’s compliance with this Section 2.3(e) and timely, accurate and effective delivery of all information to make the Avaya Endpoints compatible with ACO, and the other RingCentral Services compatible with the Avaya Endpoints, including such information, cooperation, and assistance reasonably required by either Party. Each Party further acknowledges and agrees that its failure to satisfy any such responsibilities may prevent or delay the other Party’s performance of its obligations under this Section 2.3(e). The Parties agree to work together in good faith to develop a mutually agreed process pursuant to which Avaya will sell to RingCentral certain Avaya Endpoints on commercially favorable terms.
Endpoints. Except as otherwise expressly stated to the contrary in the applicable Cloud Offer Definition or Avaya’s quotation, Avaya is not responsible for the provision of any end points or similar devices necessary to deploy Cloud Services for any Reseller or Cloud End User, including personal end points, personal computers, mobile devices and telepresence or room systems.
Endpoints. Customers may deploy endpoints of any type (e.g., Windows, MacOS, Linux, Android). There may be a limitation on the number of endpoints that may be deployed depending on the Term of the Traps ELA purchased, as explained in the table below. At purchase or at re-purchase, Customer shall forecast the number of endpoints it expects to add during the Term (“Incremental”). For 1-Year Term/SKU: There is no limit on the number of endpoints that may be deployed. For 3-Year Term/SKU: There is a limit on the number of endpoints that may be deployed: • During the first half of the Term, the cap shall be calculated as follows: Existing endpoints + 150% of Incremental • During the second half of the Term, there is no limit to the number of endpoints that may be deployed. For 5-Year Term/SKU: There is a limit on the number of endpoints deployed, as follows: • During the first 60% of the Term, the cap shall be calculated as follows: Existing endpoints + 150% of Incremental • During the remainder of the Term, there is no limit to the number of endpoints that may be deployed.
Endpoints. Chapter 2 Pre-clinical performance in the four residence areas was measured by the following time intervals (minutes): Onset of Symptoms to Alert of Emergency Services (patient delay), Onset of Symptoms to Arrival at Catheterization Room (Cath-Lab), Door to Cath-Lab (hospital delay) and Interval between the Alert of Emergency Services to Arrival at the Hospital. Additional 32 endpoints of interest were peak Troponin T and peak Creatine Phosphokinase (CPK) levels. Furthermore, risk profile for CHD was compared between the 4 areas of residency within Xxxxxxxx-Xxxxxx, including risk factors like smoking, hypertension, hyperlipidemia, positive family history, diabetes mellitus and prior myocardial infarction. Lastly, drug treat- ment before occurrence of AMI was studied. Pre-admission medication use of interest was beta-blockers, statins, aspirin, ACE-inhibitors, angiotensine II (AT2)-antagonists, diuretics and calcium-antagonists. Statistical Analysis Sample comparisons were made with a Xxxxxxx χ2 test for categorical variables using Yate’s correction where appropriate. A Kruskal-Wallis one-way analysis of variance was employed for the comparison of not normally distributed continuous variables such as time intervals. All tests were two-sided, a p-value of < 0.05 was considered significant (using Bonferroni correction where appropriate). All data were analyzed with SPSS 16.0.02. Standardized pre-hospital care of acute myocardial infarction patients 33 RESULTS Study population A total of 1002 consecutive AMI patients were admitted at the PCI center between 2006 and 2008. Of these patients, 863 (86%) were Xxxxxxxx-Xxxxxx residents and included in the final study population. Baseline characteristics are shown in Table 1. The majority of patients was male (75%) and the mean age was 61 ± 13 years. The distribution of patients from the areas of residence 1, 2, 3 and 4 was 31%, 29%, 21% and 19%, respectively (Fig. 1).
Endpoints. The primary endpoint in the oMLS cohort was LPFS, defined as the interval between baseline visit and the date of the first clinical or any radiological local progression of the target lesion. Secondary endpoints included the time to (the next line of) systemic therapy, LPFS censored at the date of the first cycle of (the next line of) systemic therapy, progression free survival (PFS), disease specific survival (DSS), overall survival (OS), and toxicity. Of note, the indication for systemic therapy was set at the discretion of the treating clinicians in the multidisciplinary sarcoma board. Acute (<3 months) and late (≥3 months) toxicities were scored during the on-treatment check-ups and follow-up visits, respectively.[30] Furthermore, if target lesions were symptomatic at baseline visit, clinical symptom reduction was evaluated at the first follow-up visit. In case of definitive RT of (predominantly) non- bone metastases, the best achieved radiological response of the target lesion was an additional secondary endpoint, with an objective radiological response defined as either complete (disappearance) or partial (maximum diameter ≤-30%) response.
Endpoints. Primary ● Time (number of days) from when participant is told they may have OSA to OSA diagnosis ○ Time (number of days) from when participant is told they may have OSA to when they receive HST prescription ○ Time (number of days) from when participant receives HST prescription to when they receive diagnosis ● Time (number of days) from OSA diagnosis to PAP therapy initiation ● Time (number of days) from therapy initiation to when 90-day compliance threshold is achieved Secondary ● Completion rates ○ Among individuals who had an HST ordered, % of individuals who completed the HST ○ Among individuals prescribed a PAP device, % of individuals who filled the order (PAP device delivered to them) ○ Among individuals prescribed a PAP device, % of individuals who used the PAP device at least once during the 90 days ● Compliance Metrics ○ Percent of participants who meet 90 day compliance success criteria, as defined by: ■ ≥ 4 hours per night on 70% of nights during a consecutive 30 day period anytime during the first 90 days Document Number
Endpoints. The impact of MS and CRP on vascular phenotype in DM2 was assessed using sonographic vascular parameters, IMT, and flow mediated dilatation (FMD), as well as the following en- dothelium-related and hemostatic factors: fibrinogen, s-thrombomodulin (sTM), tissue type plasminogen-activator (tPA), plasminogen-activator inhibitor-1 (PAI-1), sVCAM, sE-selectin, and von Willebrand factor (VWF). Laboratory investigations
